



**Press Release**

Monday, October 3, 2011



Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

BSE: 532531

NSE: STAR

---

## **STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR CLINDAMYCIN INJECTION, USP**

---

**October 3, 2011, Bangalore:** Strides Arcolab Limited (Strides) today announced that it has received US FDA approval for Clindamycin Injection, USP, an antibiotic used to treat bacterial infections.

Clindamycin Injection will be available in three single-dose vial sizes and in pharmacy bulk packaging. As with all products in Strides – Sagent JV, Clindamycin features the Prevent IV Measures packaging and labelling designed to aid in the reduction of medication errors.

According to IMS, the 2011 U.S. market for Injectable Clindamycin approximates to USD 65 million (including bags). The product is expected to be launched in early 2012.

Clindamycin is the twelfth product approved under the Sagent - Strides partnership. Strides is developing and supplying more than 25 injectable products for the USA market which will be marketed by Sagent.

### **About Agila Specialties**

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.



## **About Strides Arcolab Limited**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at [www.stridesarco.com](http://www.stridesarco.com).

For further information, please contact:

| <b><u>Strides</u></b>                                                              | <b><u>PR Consultancy</u></b>                                                                                                                          |
|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mr. V.S. Iyer, CEO - Agila<br>+91 80 6784 0111                                     | Corporate Voice   Weber Shandwick<br>Mahesh Nair,<br>+91 9880376648<br><a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a> |
| Mr. Ajay Singh : +91 80 6784 0813<br>Mr. Kannan N : +91 98450 54745<br>(Investors) | Hiba Kunil<br>+91 98807 26372<br><a href="mailto:hiba@corvoshandwick.co.in">hiba@corvoshandwick.co.in</a>                                             |

